Needham & Company Reiterates Buy on GenMark Diagnostics (GNMK) Following 4Q
Tweet Send to a Friend
Needham & Company reiterated a Buy rating and $15.00 price target on GenMark Diagnostics (NASDAQ: GNMK) following the company's 4Q ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
